RespireRx Pharmaceuticals Inc (RSPI)

[myostrain]

That diabetic finding is interesting,,, proof for probably many theories; how many calories do we normally consume,, how many do we normally burn through activity. Not nearly enough prolonged or vigorous exercise to begin to utilize the amount or types of energy we consume.

For the recent posts, cortex seems to have a very positive looking pipeline,, but just for thoughts, does GFP or anyone have a little history of all known tested compounds?
The only compound of value so far is CX717, the newer compounds may be more potent, some of them may be safer but the early findings do not mean much at this stage and especially in this market. Though the last webcast Cortex had did show high probability for success with the new low impacts in RD, enough to be eternally optimistic and to throw Buffet/Grahams' philosophy of investment out the window.

One aspect people have not discussed is the veterinary pathway for Cortex; it would seem a quicker way to bring a product to market. Why hasn't SGP come into the recent possibilities? Not quite the pain company but it fits other indications for the ampakines.
I wouldn't mind a partnership with two companies, one pain-RD collaboration and one ADHD/AD collaboration.